The The U.S. Food and Drug Administration approved the first treatment for postpartum depression. The FDA approved Zulresso (brexanolone) injection for intravenous (IV) use for postpartum depression (PPD) in adult women. This is the first drug approved by the FDA specifically for PPD.
This approval marks the first time a drug has been specifically approved to treat postpartum depression, providing an important new treatment option,” said Tiffany Farchione, M.D., acting director of the Division of Psychiatry Products in the FDA’s Center for Drug Evaluation and Research. Read the full FDA News Release.
The OWH is celebrating National Minority Month. The FDA Office of Women’s Health offers free health fact sheets and brochures in multiple languages. You can download resources in over 15 languages.
Email Emily Hamstra (email@example.com) to receive a digest of the day’s BHIC posts via email.